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ABSTRACT
Objectives Many central nervous system (CNS) 
medications are considered potentially inappropriate for 
prescribing in older people; however, these medications 
are common in polypharmacy (≥5 medicines) regimens. 
This paper aims to determine the prevalence of CNS drug 
classes commonly taken by older people. Furthermore, this 
paper aims to determine whether polypharmacy and other 
factors, previously found to be associated with overall 
polypharmacy, are associated with the most common CNS 
drug classes.
Design Cross- sectional study.
Setting English Longitudinal Study of Ageing (wave 6).
Participants 7730 participants (≥50 years).
Main outcome measures Adjusted Odds Ratios (OR) and 
95% confidence intervals (CI) for CNS drug classes.
Results 31% of the sample were currently taking ≥5 
medications (polypharmacy), of whom 58% (n=1362/2356) 
were taking CNS medicines as part of their regimen. 
The most common CNS drug classes in polypharmacy 
regimens were non- opioid analgesics, opioid analgesics, 
tricyclic and related antidepressants (TCAs) and selective 
serotonin reuptake inhibitors (SSRIs) (34.6%, 13.2%, 
10.9% and 10.4%, respectively). Compared with people 
currently taking 1–4 prescribed medicines, polypharmacy 
was associated with adjusted ORs of 5.71 (95% CI: 4.29 
to 7.61, p<0.01) for opioid analgesics, 3.80 (95% CI: 3.25 
to 4.44, p<0.01) for non- opioid analgesics, 3.11 (95% CI: 
2.43 to 3.98, p<0.01) for TCAs and 2.30 (95% CI: 1.83 to 
2.89, p<0.01) for SSRIs. Lower wealth was also associated 
with the aforementioned CNS drug classes.
Conclusion Opioid and non- opioid analgesics were 
the most prevalent classes of CNS medicines in this 
study. Polypharmacy is strongly associated with the 
aforementioned classes of analgesics. Polypharmacy is 
also associated with TCAs and SSRIs, although to a lesser 
extent than for analgesics. For all CNS medicine classes, 
polypharmacy may need to be considered in relation 
to reducing the risk of potential adverse events. After 
adjustment, lower wealth is associated particularly with 
analgesics, highlighting that socioeconomic factors may 
play a role in the prescribing of CNS medicines. These 
findings provide a baseline for future research into this 
area.
INTRODUCTION
Polypharmacy (the concurrent use of 
multiple medicines by one individual) is 
becoming more prevalent worldwide.1 Previ-
ously, we reported that ‘lower wealth, obesity, 
increasing age and the presence of chronic 
conditions were significantly associated with 
polypharmacy’, among older adults (≥50 
years) in England.2 The effect of these factors, 
on polypharmacy, is ‘likely to become more 
pronounced’ as the English population is 
ageing, and there are increasing numbers of 
individuals with multiple chronic conditions 
(multimorbidity).2 3 One major risk factor 
of morbidity is obesity, which also continues 
to be a significant public health challenge.4 
Furthermore, the broad gap in UK wealth 
inequalities persists.5 Although the afore-
mentioned factors are associated with poly-
pharmacy in general, little is known about 
whether these factors are also associated with 
certain types of medications in polypharmacy 
regimens.
Strengths and limitations of this study
 ► Detailed investigation of classes of central nervous 
system medicines and their associations between 
polypharmacy and other factors, such as age and 
wealth.
 ► This study adds to the limited literature on polyphar-
macy and specific medications.
 ► Data from a large sample of participants, with infor-
mation on current medications obtained during an 
interview by a nurse.
 ► Medications were coded according to medicine 
class (eg, selective serotonin reuptake inhibitors); 
however, specific medication details (eg, fluoxetine) 
were not available.
 ► This study was cross- sectional; therefore, we cannot 
determine the direction of causality from our data.
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Few studies have examined the composition of poly-
pharmacy in detail.6 7 Wastesson et al6 analysed a Swedish 
prescription database and reported that ‘analgesics and 
psychotropic drugs’ were commonly taken by participants 
with polypharmacy. The aforementioned types of medi-
cations were also shown to make a significant ‘contri-
bution to the overall prevalence of polypharmacy’.6 
Similarly, Bjerrum et al7 investigated whether there were 
any correlations between participant age and the compo-
sition of their medication regimens by analysing a Danish 
prescription database. Results showed that analgesics 
were commonly taken by older participants with poly-
pharmacy, while younger participants with polypharmacy 
commonly took antidepressants.7
Although the aforementioned studies6 7 reported that 
medicines which acted on the central nervous system 
(CNS) were common in polypharmacy regimens; these 
medications are often considered to be inappropriate for 
prescribing in older people, due to age- related pharma-
cokinetic and pharmacodynamic changes.8 For example, 
Beers criteria9 and the screening tool of older people's 
prescriptions and screening tool to alert to right treat-
ment criteria10 recommend that tricyclic antidepressants 
should be avoided in the elderly due to the enhancement 
of anticholinergic effects. Similarly, both tools recom-
mend that benzodiazepines should be avoided in older 
people due to the risk of prolonged sedation and falls.9 10
There may be opportunities to deprescribe some CNS 
medicines in polypharmacy regimens, particularly among 
older people. In order to identify these opportunities, 
absolute and relative measures need to be calculated. 
Absolute measures are helpful in characterising the like-
lihood of an event (eg, the prevalence of polypharmacy) 
while relative measures (eg, ORs) provide an indication 
of the extent to which an event is associated with risk 
factors (eg, the extent to which polypharmacy is associ-
ated with CNS medicines).11 The combination of absolute 
and relative measures data will enable the associations 
between polypharmacy and CNS medicines to be exam-
ined in detail.11
The aim of this study was first, to determine the prev-
alence of CNS drug classes commonly taken by older 
people (≥50 years). The second aim was to determine 
whether polypharmacy and other factors, previously 
found to be associated with overall polypharmacy, are 
associated with the most common CNS drug classes.
METHODS
Sample and participants
The English Longitudinal Study of Ageing (ELSA) 
started collecting data in 2002 from a broadly represen-
tative sample of the English population, who were aged 
over 50.12 Since then, data have been collected in face- 
to- face interviews and by the completion of written ques-
tionnaires every 2 years.12 Data have also been collected 
during nurse assessments which have taken place every 
4 years.12 This cross- sectional study analysed data collected 
between May 2012 and June 2013 (ELSA wave 6).
Overall, 10 601 older adults provided data at wave 6. 
Most of the participants (86.5%, n=9169/10 601) at wave 
6 were classified as core participants. Core participants 
are individuals who meet the following three criteria: they 
must have been living in the household at the time of 
the Health Survey for England, they must meet the age 
criteria of a given ELSA cohort (≥50 years) and they must 
have provided data in the first wave of ELSA, once invited 
to participate in the study.13 Of the core participants at 
wave 6, 84.3% (n=7730/9169) completed the nurse inter-
view and the latter group are the focus of the current 
study.
Patient and public involvement
No patients were involved in the development of the 
research question, study design or data interpretation in 
this study.
Ethical approval
The National Research and Ethics Committee have 
ethically approved all ELSA waves under the National 
Research and Ethics Service (NRES). Informed written 
consent has been provided by all ELSA participants, and 
their data are stored anonymously.14 ELSA data can be 
accessed via the UK Data Service Discover.15 Participants 
were not involved in the current study; therefore, addi-
tional ethical approval was not necessary.
Inclusion criteria
Core participants must have successfully completed a 
nurse assessment, a face- to- face interview, and a written 
questionnaire at wave 6 to be eligible for inclusion in the 
current study.
Data collection
Details about current medication usage were collected 
during the nurse assessment. Participants were asked 
‘Could I take down the names of the medicines, including 
pills, syrups, ointments, puffers or injections, prescribed 
for you by a doctor or a nurse?’.16 The nurse interviewer 
then verified participant answers by asking to see the 
original medication container and sought to determine 
whether the medication was current by asking ‘Have 
you taken/used the medication in the last 7 days?’.16 All 
current medication details were converted into a six- digit 
code by the nurse interviewer, according to the British 
National Formulary (Edition 61) chapter and subsec-
tion.17 For example, non- opioid analgesics were coded as 
040701, where the first two digits represented the BNF 
chapter (Chapter 4—CNS), the next two digits repre-
sented the type of medication (analgesics) and the final 
two digits represented the medication class.18 The nurse 
interviewer coded up to 27 different prescribed medi-
cines per participant.19
In addition to gathering information about current 
medication usage, the nurse interviewer recorded demo-
graphic data and took a number of measurements, 
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including weight and height.16 These measurements 
were used to calculate each participants body mass index 
(BMI). In the current study, obesity was defined as a 
BMI ≥30 kg/m2; overweight weight was defined as a BMI 
between 25.0 kg/m2 and 29.9 kg/m2; normal weight was 
defined as a BMI between 18.5 kg/m2 and 24.9 kg/m2 and 
underweight was defined as a BMI ≤18.5 kg/m2.20
Further demographical data and health data were 
collected by trained interviewers during the face- to- face 
interviews. Participants were asked the following question 
‘Do you have any long- standing illness, disability or infir-
mity?’ and answers were recorded as ‘yes’ or ‘no’.21 Data 
about monies received through employment, pensions, 
benefits, savings and investments were also collected 
by the interviewers.21 Participants provided informa-
tion about their physical assets too. With the exception 
of pension wealth, household wealth was calculated by 
summating the aforementioned financial data less any 
debts (eg, mortgage). Household wealth data were used 
when allocating participants to a wealth quintile, where 
quintile 1 was highest wealth and quintile 5 was lowest 
wealth.
Finally, participants provided information regarding 
their lifestyle choices over the past 12 months in the 
face- to- face interview and written questionnaire.21 22 Rare 
alcohol consumption was defined as drinking alcohol 
less than two times a month, frequent alcohol consump-
tion was defined as drinking alcohol between one and 
four times per week; whereas, very frequent alcohol was 
defined as drinking alcohol more than five times per 
week.23 Smoking habits over the past 12 months were 
ascertained and participants were categorised as either 
smokers, ex- smokers or non- smokers.
Definitions
Polypharmacy was defined as five or more currently 
prescribed medications, while non- polypharmacy was 
defined as one to four currently prescribed medications. 
These definitions have been used in other studies.24
Data analysis
Participants were allocated to one of the following three 
groups according to the number of prescribed medicines 
they were currently taking: no medicines, 1–4 medicines 
(non- polypharmacy) and ≥5 medicines (polypharmacy). 
Each group were profiled according to participant demo-
graphics. Participants taking no current medicines were 
excluded from the main analyses. Descriptive statistics 
were used to profile current medication usage according 
to BNF chapters.17 Following this, the most common BNF 
Chapter 4 (CNS) drug classes were identified. Logistic 
regression was used to determine the adjusted ORs for 
the associations between polypharmacy and the most 
common CNS drug classes. Additionally, logistic regres-
sion was used to determine whether the factors associ-
ated with polypharmacy in general, were also associated 
with the most common CNS drug classes. The following 
drug classes were selected because they were taken by at 
least 10% of participants with polypharmacy: non- opioid 
analgesics, opioid analgesics, tricyclic and related antide-
pressants (TCAs) and selective serotonin reuptake inhib-
itors (SSRIs). ORs with corresponding 95% CIs were 
calculated for the aforementioned CNS drug classes. All 
models were adjusted for the following covariates: poly-
pharmacy, age, gender, the presence of long- standing 
conditions, BMI, smoking, alcohol consumption over the 
past 12 months and wealth. The minimum sample size 
required for the models was 230.25 Missing data were 
coded as ‘missing’ and were included (but not reported) 
as a separate category in the models.26 A p value of 0.05 or 
less was considered to be statistically significant. All anal-
yses were undertaken using SPSS V.24.0.
RESULTS
Participant characteristics
Of the 7730 study participants, 30.5% (n=2356/7730) were 
currently taking five or more prescribed medicines (poly-
pharmacy), while 45.7% (n=3532/7730) were currently 
taking between one and four prescribed medicines (non- 
polypharmacy) (table 1). Participants with polypharmacy 
were older (mean age 68.6 years) in comparison to partic-
ipants with non- polypharmacy (mean age 66.1 years) and 
participants taking no medicines (mean age 62.1 years). 
There were also more women than men in all groups 
(table 1).
Participants provided further details about their 
current medication usage during the nurse interview at 
wave 6. Results are presented in terms of BNF chapters 
in table 1.17 Cardiovascular medicines (BNF Chapter 2) 
were taken by 90.6% (n=2135/2356) of participants with 
polypharmacy. Other common types of medications taken 
by participants with polypharmacy included gastrointes-
tinal medicines (BNF Chapter 1), CNS medicines (BNF 
Chapter 4) and endocrine medicines (BNF Chapter 6) 
(54.0%, 57.8% and 45.6%, respectively) (table 1). In 
comparison to the polypharmacy group, fewer partic-
ipants in the non- polypharmacy group were taking 
cardiovascular medicines (BNF Chapter 2), CNS medi-
cines (BNF Chapter 4), gastrointestinal medicines (BNF 
Chapter 1) and endocrine medicines (BNF Chapter 6) 
(58.6%, 23.8%, 18.5% and 19.7% respectively) (table 1).
Medications which acted on the CNS were the focus of 
the current study; therefore, BNF Chapter 4 data were 
stratified according to drug class (table 2). Non- opioid 
analgesics were taken by 34.6% (n=816/2356) of partic-
ipants with polypharmacy. Other common drug classes 
taken by participants with polypharmacy included opioid 
analgesics, TCAs and SSRIs (13.2%, 10.9% and 10.4%, 
respectively) (table 2). The aforementioned drug classes 
were also most commonly taken by participants in the 
non- polypharmacy group; however, they were taken by 
fewer participants (8.9%, 2.0%, 3.5% and 5.2%, respec-
tively) (table 2).
Logistic regression was used to determine the adjusted 
ORs for the associations between polypharmacy and the 
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Table 1 Participant characteristics at wave 6 (n=7730)
Participant characteristics
Participants with no 
medicines (n=1842) 
(%)
Participants with 1–4 
medicines (n=3532) (%)
(non- polypharmacy)
Participants with ≥5 
medicines (n=2356) (%)
(polypharmacy)
Age (years)
  50–59 732 (39.7) 719 (20.4) 244 (10.4)
  60–69 802 (43.5) 1482 (42.0) 728 (30.8)
  70–84 281 (15.3) 1174 (33.2) 1170 (49.7)
  ≤85 27 (1.5) 157 (4.4) 214 (9.1)
Gender
  Male 860 (46.7) 1536 (43.5) 1052 (44.7)
  Female 982 (53.3) 1996 (56.5) 1304 (55.3)
Long- standing condition
  No 1432 (77.7) 1621 (45.9) 388 (16.5)
  Yes 410 (22.3) 1911 (54.1) 1968 (83.5)
BMI
  BMI <18.5 kg/m2: underweight 15 (0.8) 34 (1.0) 20 (0.8)
  BMI 18.5–24.9 kg/m2: normal 645 (35.0) 892 (25.3) 421 (17.9)
  BMI 25.0–29.9 kg/m2: overweight 757 (41.1) 1485 (42.0) 787 (33.4)
  BMI >30 kg/m2: obese 397 (21.6) 995 (28.2) 935 (39.7)
Alcohol consumption in past 12 months
  Never 130 (7.1) 350 (9.9) 442 (18.8)
  Rarely 221 (12.0) 518 (14.7) 412 (17.5)
  Frequently 670 (36.4) 1154 (32.7) 643 (27.3)
  Very frequently 669 (36.3) 1212 (34.3) 579 (24.6)
Smoking
  Never smoked 816 (44.3) 1396 (39.5) 694 (29.5)
  Ex- smoker 784 (42.6) 1784 (50.5) 1364 (57.9)
  Current smoker 242 (13.1) 352 (10.0) 298 (12.6)
Wealth
  Wealth quintile 1 (highest wealth) 506 (27.5) 857 (24.3) 380 (16.1)
  Wealth quintile 2 429 (23.3) 791 (22.4) 453 (19.2)
  Wealth quintile 3 356 (19.3) 704 (19.9) 492 (20.9)
  Wealth quintile 4 262 (14.2) 615 (17.4) 575 (24.4)
  Wealth quintile 5 (lowest wealth) 243 (13.2) 489 (13.8) 432 (18.3)
Currently prescribed medications by BNF 
chapter17
  BNF Chapter 1 (gastrointestinal system) 653 (18.5) 1273 (54.0)
  BNF Chapter 2 (cardiovascular system) 2071 (58.6) 2135 (90.6)
  BNF Chapter 3 (respiratory system) 404 (11.4) 738 (31.3)
  BNF Chapter 4 (central nervous system) 842 (23.8) 1362 (57.8)
  BNF Chapter 5 (infections) 104 (2.9) 163 (6.9)
  BNF Chapter 6 (endocrine system) 696 (19.7) 1075 (45.6)
  BNF Chapter 7 (obstetrics, gynaecology and 
urinary tract disorders)
182 (5.2) 336 (14.3)
  BNF Chapter 8 (malignant disease and 
immunosuppression)
54 (1.5) 66 (2.8)
  BNF Chapter 9 (nutrition and blood) 248 (7.0) 576 (24.4)
  BNF Chapter 10 (musculoskeletal and joint 
diseases)
359 (10.2) 617 (26.2)
Continued
copyright.
 o
n
 Septem
ber 21, 2020 at University of Keele. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034346 on 14 September 2020. Downloaded from 
5Slater N, et al. BMJ Open 2020;10:e034346. doi:10.1136/bmjopen-2019-034346
Open access
most common CNS drug classes. Additionally, logistic 
regression was used to determine whether the factors 
associated with polypharmacy, in general, were also asso-
ciated with the most common CNS drug classes. The 
following CNS drug classes were selected because they 
were taken by at least 10% of participants with polyphar-
macy: non- opioid analgesics, opioid analgesics, TCAs and 
SSRIs (table 2). All models were adjusted for polyphar-
macy, age, gender, the presence of long- standing condi-
tions, BMI, smoking, alcohol consumption and wealth. 
Logistic regression results are presented in table 3.
DISCUSSION
The most prevalent CNS drug classes taken by study 
participants (≥50 years) were non- opioid analgesics, 
opioid analgesics, TCAs and SSRIs (19.2%, 6.5%, 6.5% 
and 7.3%, respectively). The prevalence of CNS drug 
classes was also considered in relation to polypharmacy. 
In the current study, there were 2356 participants with 
polypharmacy (≥5 prescribed medicines), of whom 
57.8% (n=1362) were currently taking CNS medicines. 
In contrast, fewer participants in the non- polypharmacy 
group (1–4 prescribed medicines) were currently taking 
CNS medicines (23.8%, n=842/3532).
Polypharmacy was associated with an adjusted OR 
of 5.71 (95% CI: 4.29 to 7.61, p<0.01) for opioid anal-
gesics and 3.80 (95% CI: 3.25 to 4.44, p<0.01) for non- 
opioid analgesics. These findings advance the existing 
literature by showing the magnitude of the association 
between polypharmacy and analgesics.6 27 One explana-
tion offered for the aforementioned association is that 
pain commonly co- exists with other chronic conditions, 
and polypharmacy may be used to manage these morbid-
ities.28 29 However, this approach may increase an indi-
vidual’s exposure to the adverse effects associated with 
analgesics, as polypharmacy increases the opportunity 
for drug–drug interactions and adverse drug reactions to 
occur.30 31 Further work is needed to explore alternative 
reasons why individuals with polypharmacy are three to 
four times more likely to be taking analgesics as part of 
their medication regimen, compared with individuals in 
the non- polypharmacy group.
Participant characteristics
Participants with no 
medicines (n=1842) 
(%)
Participants with 1–4 
medicines (n=3532) (%)
(non- polypharmacy)
Participants with ≥5 
medicines (n=2356) (%)
(polypharmacy)
  BNF Chapter 11 (eye) 124 (3.5) 262 (11.1)
  BNF Chapter 12 (ear, nose and oropharynx) 87 (2.5) 168 (7.1)
  BNF Chapter 13 (skin) 85 (2.4) 168 (10.0)
BMI, body mass index; BNF, British National Formulary.
Table 1 Continued
Table 2 Current usage of BNF Chapter 4 (central nervous system) medications by drug class (n=5888)
BNF Chapter 4 (central nervous system)17
Participants with 1–4 
medicines (n=3532) (%)
(non- polypharmacy)
Participants with ≥5 
medicines (n=2356) (%) 
(polypharmacy)
Non- opioid analgesics 313 (8.9) 816 (34.6)
Opioid analgesics 69 (2.0) 311 (13.2)
Tricyclic and related antidepressant drugs 123 (3.5) 258 (10.9)
Selective serotonin reuptake inhibitors 185 (5.2) 246 (10.4)
Antiepileptics 46 (1.3) 131 (5.6)
Hypnotics 31 (0.9) 103 (4.4)
Drugs used in nausea and labyrinth disorders 44 (1.2) 101 (4.2)
Other antidepressant drugs 31 (0.9) 82 (3.5)
Drugs for the treatment of Parkinson’s disease 27 (0.8) 44 (1.9)
Anxiolytics 12 (0.3) 35 (1.5)
Antimigraine drugs 52 (1.5) 38 (1.5)
Antipsychotics 20 (0.6) 32 (1.4)
Drugs for the treatment of neuropathic pain 11 (0.3) 24 (1.0)
Drugs for the treatment of dementia 9 (0.3) 10 (0.4)
Drugs for the treatment of dependence (alcohol, nicotine and opioid) 8 (0.2) 9 (0.4)
Drugs for the treatment of dystonia and other involuntary movements 13 (0.3) 7 (0.3)
copyright.
 o
n
 Septem
ber 21, 2020 at University of Keele. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034346 on 14 September 2020. Downloaded from 
6 Slater N, et al. BMJ Open 2020;10:e034346. doi:10.1136/bmjopen-2019-034346
Open access 
Table 3 Logistic regression to determine the associations between polypharmacy, participant characteristics and the usage 
of non- opioid analgesics, opioid analgesics, TCAs and SSRIs in ELSA participants (n=5888)
Participant characteristics
Adjusted OR (95% CI)
Non- opioid analgesics 
(n=1129)
Opioid analgesics
(n=380)
TCAs
(n=381)
SSRIs
(n=431)
Polypharmacy
Non- polypharmacy (1–4 
medicines)
Reference
Polypharmacy
(≥5 medicines)
3.80 (3.25 to 4.44), 
p<0.01
5.71 (4.29 to 7.61), 
p<0.01
3.11 (2.43 to 3.98), 
p<0.01
2.30 (1.83 to 2.89), 
p<0.01
Age (years)
50–59 Reference
60–69 1.21 (0.96 to 1.53), 
p=0.11
0.88 (0.63 to 1.21), 
p=0.42
0.82 (0.61 to 1.11), 
p=0.20
0.64 (0.49 to 0.82), 
p<0.01
70–84 1.49 (1.18 to 1.89), 
p<0.01
0.66 (0.47 to 0.93), 
p=0.02
0.51 (0.37 to 0.70), 
p<0.01
0.28 (0.21 to 0.37), 
p<0.01
≥85 1.82 (1.31 to 2.54), 
p<0.01
0.75 (0.45 to 1.24), 
p=0.26
0.25 (0.13 to 0.48), 
p<0.01
0.24 (0.14 to 0.41), 
p<0.01
Gender
Male Reference
Female 1.40 (1.21 to 1.63), 
p<0.01
1.43 (1.13 to 1.81), 
p<0.01
2.36 (1.84 to 3.02), 
p<0.01
1.74 (1.40 to 2.17), 
p<0.01
Long- standing condition
No Reference
Yes 1.98 (1.64 to 2.38), 
p<0.01
2.50 (1.74 to 3.59), 
p<0.01
1.59 (1.19 to 2.12), 
p<0.01
1.17 (0.91 to 1.49), 
p=0.22
BMI
Normal Reference
Overweight 1.34 (1.09 to 1.65), 
p<0.01
0.85 (0.61 to 1.17), 
p=0.31
1.30 (0.94 to 1.80), 
p=0.11
0.95 (0.72 to 1.26), 
p=0.71
Obese 1.62 (1.31 to 1.99), 
p<0.01
0.94 (0.69 to 1.28), 
p=0.69
1.29 (0.94 to 1.78), 
p=0.12
0.95 (0.72 to 1.26), 
p=0.73
Smoking
Non- smoker Reference
Ex- smoker 1.24 (1.05 to 1.46), 
p<0.01
1.37 (1.05 to 1.79), 
p=0.02
1.28 (0.99 to 1.64), 
p=0.06
1.37 (1.08 to 1.74), 
p<0.01
Current smoker 1.40 (1.10 to 1.79), 
p<0.01
1.92 (1.36 to 2.71), 
p<0.01
1.35 (0.95 to 1.92), 
p=0.09
1.77 (1.29 to 2.42), 
p<0.01
Alcohol consumption
Never Reference
Rarely 0.79 (0.62 to 0.99), 
p=0.04
1.04 (0.76 to 1.45), 
p=0.78
0.86 (0.61 to 1.20), 
p=0.36
0.85 (0.60 to 1.21), 
p=0.37
Frequently 0.73 (0.58 to 0.90), 
p<0.01
0.55 (0.39 to 0.77), 
p<0.01
0.81 (0.59 to 1.11), 
p=0.19
0.83 (0.60 to 1.16), 
p=0.27
Very frequently 0.67 (0.54 to 0.85), 
p<0.01
0.54 (0.38 to 0.78), 
p<0.01
0.54 (0.38 to 0.78), 
p<0.01
0.89 (0.63 to 1.25), 
p=0.51
Wealth
Wealth quintile 1 (highest) Reference
Wealth quintile 2 1.27 (0.98 to 1.63), 
p=0.07
1.78 (1.16 to 2.72), 
p<0.01
1.06 (0.73 to 1.54), 
p=0.77
1.45 (1.02 to 2.06), 
p=0.04
Wealth quintile 3 1.37 (1.07 to 1.77), 
p<0.01
1.26 (0.81 to 1.97), 
p=0.31
0.98 (0.67 to 1.44), 
p=0.93
1.37 (0.96 to 1.97), 
p=0.09
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Findings also showed that polypharmacy was asso-
ciated with an adjusted OR of 3.11 (95% CI: 2.43 to 
3.98, p<0.01) for TCAs and 2.30 (95% CI: 1.83 to 2.89, 
p<0.01) for SSRIs. It is difficult to compare these find-
ings to the existing literature because a recent systematic 
review showed that ‘there is almost no data available on 
antidepressant prescribing in older adults treated with 
polypharmacy’.32
Logistic regression showed that other factors, including 
age, gender and wealth, were also associated with the 
most common CNS drug classes. Individuals aged over 60 
years were less likely to take opioid analgesics, TCAs and 
SSRIs, compared with individuals aged 50–59 years. Low 
prioritisation of pain, fears about opioid side effects and 
concerns about tolerance or dependence, are some of the 
reasons previously cited to explain why older people are 
less likely to take opioid analgesics in their medication 
regimens.33 However, our findings, in relation to age and 
antidepressant usage, are different to those reported in 
previous studies thus, requiring further exploration.34 35
Women were more likely to take analgesics, TCAs and 
SSRIs, compared with men. Craftman et al36 reported 
similar findings when they examined medication usage 
in older adults, over a 20- year period. One possible expla-
nation for our analgesic findings could be that there are 
gender differences in relation to pain. Pain is more prev-
alent in women, and often reported to be more severe, 
compared with men; however, the underlying aetiology is 
not fully understood.37
Lower wealth was associated with non- opioid anal-
gesics (adjusted OR 2.40; 95% CI: 1.86 to 3.12, p<0.01) 
and opioid analgesics (adjusted OR 2.49; 95% CI: 1.63 to 
3.80, p<0.01). High levels of unemployment, high prev-
alence of chronic pain and limited access to specialist 
pain services, in deprived socioeconomic areas, have 
been previously cited as reasons behind the association 
between lower wealth and analgesics.38 39 It has also been 
suggested that among people with lower socioeconomic 
status (SES), disability rates are higher when compared 
with people with higher SES reporting the same inten-
sity of pain40 Lower wealth was also associated with TCAs 
(adjusted OR 1.52; 95% CI: 1.05 to 2.21, p=0.03) and 
SSRIs (adjusted OR 1.55; 95% CI: 1.07 to 2.23, p=0.02). 
While we acknowledge that TCAs and SSRIs are not 
always indicated for the treatment of depression, these 
findings complement previously published research, 
which showed that lower wealth was significantly associ-
ated with depression in ELSA participants.41
This study has some key strengths. Data from 7730 
participants were included in our analyses. Moreover, this 
is the first study to examine the associations between poly-
pharmacy and CNS medicines, in detail, by examining 
absolute and relative measures. Our analyses also enabled 
us to examine the associations between the most common 
CNS drug classes and a wide range of other factors. 
Furthermore, the potential for residual confounding was 
minimised by adjusting for a range of health, lifestyle and 
economic covariates in our analyses.
Despite the aforementioned strengths, this study has 
several limitations. This study was cross- sectional; there-
fore, we cannot determine the direction of causality from 
our data. Furthermore, the nurse interviewer coded 
participant’s medications according to BNF chapter 
and drug class (eg, SSRIs); however, they were unable 
to record specific medication (eg, fluoxetine) or combi-
nation medication data. This may need to be taken into 
consideration when future work is conducted into CNS 
medicines and polypharmacy.
Opioid and non- opioid analgesics were the most preva-
lent classes of CNS medicines in this study. Polypharmacy 
is strongly associated with the aforementioned classes of 
analgesics. Polypharmacy is also associated with TCAs and 
SSRIs, although to a lesser extent than for analgesics. For 
all CNS medicine classes, polypharmacy may need to be 
considered in relation to reducing the risk of potential 
adverse events. After adjustment, lower wealth is associ-
ated particularly with analgesics, highlighting that socio-
economic factors may play a role in the prescribing of 
CNS medicines. These findings provide a baseline for 
future research into this area.
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